November 22nd 2024
A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.
November 21st 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Abemaciclib Leads to Positive Benefit in Chinese Women With HR+ Breast Cancer
September 30th 2019CDK4/6 inhibitor abemaciclib plus endocrine therapy led to significant benefits in a population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer, according to data from 2 randomized trials presented at the 2019 ESMO Congress.
Read More
Larotrectinib Maintains Safety and High Efficacy in TRK Fusion-Positive Cancer
September 29th 2019Three clinical trials presented at the 2019 ESMO Congress show that the tropomyosin receptor kinase inhibitor larotrectinib continues to show anti-tumor activity, including long-lasting objective responses and low toxicity, according to results from an integrated analysis.
Read More
Abemaciclib/Fulvestrant Demonstrates Overall Survival Benefit in HR+ Advanced Breast Cancer
September 29th 2019Results from the phase III MONARCH 2 trial showed that the addition of the CDK4/6 inhibitor abemaciclib to fulvestrant improved overall survival by 9.4 months compared with fulvestrant and placebo in patients with hormone receptor–positive, HER2-negative advanced breast cancer who progressed on prior endocrine therapy, according to data presented at the 2019 ESMO Congress.
Read More
Subpar Concordance Seen With PD-L1 Assays in Advanced TNBC
September 29th 2019A subgroup of patients with triple-negative breast cancer who had immune cell PD-L1 expression, by the SP142 immunohistochemistry assay had responses to atezolizumab and nab-paclitaxel, regardless of whether they had primary or metastatic disease, according to an exploratory biomarker substudy of IMpassion130.
Read More
HR+/HER2+ Breast Cancer PFS Improved With Abemaciclib
September 29th 2019Patients with advanced hormone receptor–positive, HER2-positive breast cancer had improved progression-free survival when receiving the CDK4/6 inhibitor abemaciclib and endocrine therapy with trastuzumab compared with trastuzumab and chemotherapy, according to findings from the randomized phase II monarcHER trial.<sup>1</sup>
Read More
OS Improved in Advanced HR+/HER2- Breast Cancer With Ribociclib/Fulvestrant
September 29th 2019Ribociclib with fulvestrant resulted in a clinically significant overall survival benefit compared with placebo in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to findings from the phase III MONALEESA-3 trial presented at the 2019 ESMO Congress.
Read More
Prolonged pCR Rates Seen in TNBC With Neoadjuvant Pembrolizumab and Chemotherapy
September 29th 2019Patients with early triple-negative breast cancer receiving neoadjuvant treatment with the combination of pembrolizumab and chemotherapy showed extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone in the phase III KEYNOTE-522 study.
Read More
Phase II Trial Shows Improved Survival in TNBC With Trilaciclib
September 29th 2019A randomized phase II study with patients with metastatic triple-negative breast cancer showed unexpected improved overall survival with the addition of trilaciclib, an investigational CDK4/6 inhibitor, to gemcitabine and cisplatin, even though the combination failed to meet a safety-related primary endpoint.
Read More
Overall Survival May Improve With the Addition of Atezolizumab to T-DM1 for HER2+ Breast Cancer
September 29th 2019The addition of atezolizumab to ado-trastuzumab emtansine improved overall survival in patients with previously treated HER2-positive advanced breast cancer compared with T-DM1 alone, according to a second OS analysis of the phase II KATE2 trial presented at the 2019 ESMO Congress.
Read More
Pertuzumab Combo Not Inferior to Standard IV Infusions in HER2+ Breast Cancer
September 19th 2019The phase III FeDeriCa trial found that a fixed-dose subcutaneous injection of pertuzumab and trastuzumab with hyaluronidase in combination with intravenous chemotherapy was pharmacokinetically noninferior to the standard IV infusions of the regimen in patients with HER2-positive breast cancer.<br />
Read More
FDA Warns of Lung Inflammation From CDK4/6 Inhibitor Use in Breast Cancers
September 16th 2019The FDA has issued a warning for a rare, but severe, lung inflammation that could be caused by the use of CDK4/6 inhibition in patients with advanced breast cancers. The warning applies to treatment with palbociclib, ribociclib, and abemaciclib specifically, but warnings of the risk of lung inflammation have been approved to be added to the prescribing information for the entire class of CDK4/6 inhibitors.
Read More
Expert Highlights Emerging Agents for Metastatic HER2+ Breast Cancer
September 16th 2019In an interview with Targeted Oncology, Charles Geyer, MD, discussed the potential role of neratinib as well as other new agents that are coming down the pipeline for the treatment of patients with metastatic HER2-positive breast cancer. He also addressed the biggest challenges oncologists face in managing this disease.
Read More
FDA Accepts sNDA for Neratinib Combo for Third-Line HER2+ Metastatic Breast Cancer
September 11th 2019The FDA has accepted a supplemental New Drug Application for the use of neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer following failure of ≥2 prior lines of HER2-directed therapy.
Read More
Liquid Biopsy Assay Identifies Responses to Neoadjuvant Therapy in Early-Stage Breast Cancer
September 7th 2019In an interview with Targeted Oncology, Muhammed Murtaza, MBBS, PhD, discussed the role for TARDIS in the treatment landscape of early-stage breast cancer, as well as the data supporting its use. He also highlighted next steps necessary for validating these results and the potential clinical value of liquid biopsies in the breast cancer space.
Read More
Providing Predictive and Prognostic Biomarkers for Breast Cancer From the TAILORx Trial
September 6th 2019Jesus Anampa, MD, MS, assistant professor, Department of Medicine, Albert Einstein School of Medicine, says in the past, most patients with breast cancer were treated with chemotherapy. In some cases, these patients were being over-treated. To limit the use of chemotherapy in patients who don’t need it, a group of researchers conducted the TAILORx trial.
Watch
USPSTF Finalizes Recommendation on Therapies for Reducing Breast Cancer Risk
September 6th 2019The United States Preventive Services Task Force is recommending that therapies like tamoxifen, raloxifene, or aromatase inhibitors be administered to women who have a high risk for developing breast cancer and low risk for the adverse events that may be caused by these therapies. This recommendation is part of an update to the USPSTF recommendation statement on treatments for reducing breast cancer risk.
Read More
Analyzing Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer
September 4th 2019Angela DeMichele, MD, MSCE, discusses predictors of response to neoadjuvant chemotherapy in various subgroups of patients with breast cancer. Selecting characteristics of patients who will most likely benefit from this therapy is not an exact science, she adds.
Watch
Europe Approves Atezolizumab Plus Nab-Paclitaxel for Frontline Treatment of TNBC
August 29th 2019The combination of atezolizumab and nab-paclitaxel has been approved by the European Commission as a frontline treatment for adult patients with unresectable, locally advanced, or metastatic PD-L1–positive triple-negative breast cancer, a result of the positive outcomes in the phase III IMpassion130 trial.
Read More
In an interview with <em>Targeted Oncology,</em> Carol Mangione, MD, MSPH, a co-author on the USPSTF Recommendation Statement, gave insight into the specifics of the recommendations and how the Task Force hopes these suggestions will impact patient outcomes.<br />
Read More
CDK4/6 Inhibitor Combinations Could Have Lasting Benefits in ER+ Metastatic Breast Cancer
August 21st 2019CDK4/6 inhibitors<strong> </strong>offer clear benefits in pro­gression-free survival, delayed time to chemotherapy, and overall survival in both pre and postmenopausal patients with estrogen receptor-positive metastatic breast cancer, said Angela DeMichele, MD, MSCE.
Read More
Practical Assessment Tools Guide Treatment Decisions in Geriatric Oncology
August 21st 2019In a presentation at the <em>18th Annual </em>International Congress on the Future of Breast Cancer® East, hosted by Physicians’ Education Resource®, LLC, in New York, Armin Shahrokni, MD, MPH, emphasized the importance of performing a comprehensive geriatric assessment for each patient to determine optimal treatment.
Read More
Although Barriers to Treating Brain Metastases Exist, Systemic Therapies Make Progress
August 15th 2019The American Society of Clinical Oncology and Friends of Cancer Research have issued a joint research statement that broadens eligibility criteria affecting 2 patient subgroups: patients with treated/stable brain metastases and those with new, active, or progressive brain metastases.<br />
Read More
Strategies for Overcoming CDK4/6 Inhibition Emerge in ER+ Breast Cancer
August 13th 2019Both cell cycle-specific and nonspecific mechanisms that lead to acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer have resulted in multiple promising agents and combinations for the second-line management of metastatic disease.
Read More
Expert Argues the Case for Whole Breast Irradiation as Standard of Care for Breast Cancer
August 12th 2019Reporting on the debate with his peer, Lawrence J. Solin, MD, FACR, FASTRO explained his stance on whole breast irradiation in comparison with partial breast irradiation in breast cancer treatment during an interview with <em>Targeted Oncology</em>. More research is needed to support the idea that PBI can be used for more patients, according to Solin.
Read More
Evaluating the Role of Neoadjuvant Endocrine Therapy in Breast Cancer
August 1st 2019Sara M. Tolaney, MD, MPH, discusses the evolving role of neoadjuvant endocrine therapy in the breast cancer space. She says there is particular interest in using this therapy in patients with HER2-positive and triple-negative breast cancer, but it can be more challenging in patients with ER-positive disease.
Watch
OS Benefit With Ribociclib Seen Across HR+/HER2- Breast Cancer Settings
August 1st 2019Ribociclib in combination with fulvestrant demonstrated a statistically significant improvement in overall survival in postmenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to interim results from the phase III MONALEESA-3 trial.
Read More